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Abstract. De novo CD5-positive diffuse large B- cell lymphoma (CD5+ DLBCL) is a subtype of DLBCL
found predominantly in older individuals. This particular subtype has been associated with a female pre-
dominance and a more aggressive clinical course. Conversely, this entity has not been described in the pe-
diatric population. We report a case of a 12 year-old boy who presented with an ileocecal intussusception.
Radiologic, morphologic, and immunophenotypic analysis revealed an isolated extranodal mass consistent
with a CD5+ DLBCL, germinal center cell phenotype. Fluorescent in situ hybridization analysis was nega-
tive for cMYC, BCL6, BCL2, MLL, and IGH/CCND1 rearrangement and showed loss of one copy of MLL
in 32% cells. The patient was treated with four cycles of cyclophosphamide, vincristine, prednisolone,
methotrexate, and doxorubicin and achieved complete remission. To the best of our knowledge, this is the
first detailed report of a de novo CD5+ DLBCL occurring in a child.
Introduction
Diffuse large B-cell lymphoma (DLBCL) compris-
es 40% of adult non-Hodgkin lymphomas in west-
ern countries and approximately 15-20% of non-
Hodgkin lymphomas in the pediatric population
[1,2]. The World Health Organization (WHO)
classification scheme currently includes DLBCL
under several headings, recognizing specific mor-
phological, immunophenotypic, and molecular
variants, which correspond to noteworthy differ-
ences in biologic behavior and clinical outcome [1].
While not yet recognized as a separate entity by the
WHO, de novo CD5-positive DLBCL (CD5+
DLBCL) has been increasingly described by several
groups since the initial report in 1995 [3]. These
lymphomas comprise approximately (5–10%) of
DLBCLs [4], have been shown to arise in older in-
dividuals, and show a female predominance. They
are associated with a more aggressive disease course
[5]; patients often present with increased extrano-
dal and central nervous system (CNS) involvement
and more commonly have increased lactate dehy-
drogenase (LDH) levels. The majority of cases be-
long to the activated B- cell (ABC) subtype, and
associations with specific chromosomal aberrations
and molecular features have been reported [5-7].
Conversely, de novo CD5+ DLBCL have not been
studied in the pediatric population. We report a
case of a pediatric de novo CD5+ DLBCL, discuss
its clinicopathological and fluorescent in situ hy-
bridization (FISH) findings, and provide a brief
review of the literature.
Materials and Methods
Case Selection. We searched our departmental archives
from July 2004 to July 2014 for cases of high grade
B-cell lymphoma (defined by a Ki-67 proliferation index
of ≥90%) and pediatric lymphoma simultaneously in
order to identify cases with aberrant CD5 expression.
The pediatric age range was defined as 0 to 19 years.
Morphologic Evaluation. Hematoxylin and eosin
(H&E) stained, formalin-fixed, paraffin-embedded tis-
sue sections were reviewed. Air-dried Wright-Giemsa-
stained bone marrow (BM) aspirate smears and H&E
stained sections of bouins-fixed, paraffin-embedded
bone marrow biopsy cores were assessed.
0091-7370/15/0500-574. © 2015 by the Association of Clinical Scientists, Inc.
Annals of Clinical & Laboratory Science, vol. 45, no. 5, 2015
Address correspondence to Amy Coffey, MD; Department of
Pathology and Cell Biology, Columbia University Medical Center,
622 West 168th Street, PH 15 West 1574, New York, NY 10032,




marker analysis was performed using antibodies against
CD5, CD10, CD20, CD21, CD23, bcl2, bcl6, TdT,
CD56, CD34, CD3 (Leica Biosystems, Nussloch GmbH,
Germany), CD43, CD79a, CD44, CD30, CD138,
MUM1, Cyclin D1, Ki-67 (Ventana Medical Systems,
Inc., Tucson, Arizona, USA), HGAL, FoxP1, SOX11,
LMO2 (Cell Marque, Inc., Rocklin, CA, USA), and c-Myc
(Abcam plc., Cambridge, England, UK). In situ hybridiza-
tion for Epstein Barr virus encoded RNA (EBER) was also
performed (Ventana Medical Systems, Inc., Tucson,
Arizona, USA).
Flow cytometric immunophenotyping was performed on
cell suspensions using FACScalibur (BD Bioscience, San
Jose, CA) according to standard procedures with monoclo-
nal antibodies consisting of CD45, CD19, CD20, FMC7,
cytoplasmic CD79a, CD3, CD5, CD23, CD43, CD10,
CD11c, CD25, CD103, CD13, CD33, CD117, CD38,
CD138, CD56, surface and cytoplasmic kappa and lambda
light chains, surface and cytoplasmic IgM, and surface IgD
(BD Bioscience, San Jose, CA). For each antibody, negative
staining levels were set by comparison with an isotype-
matched control. Data analysis was performed using FACS
Diva software (BD Bioscience, San Jose, CA).
Cytogenetic Analysis and Fluorescence in Situ
Hybridization. Conventional cytogenetic analysis
was performed on metaphase cells from BM aspirate
cultured for 24 h using standard techniques. Giemsa
banded metaphases were analyzed and described ac-
cording to International System for Human
Cytogenetic Nomenclature 2009 [8]. Fluorescence in
situ hybridization (FISH) for cMYC, BCL6, BCL2,
MLL, and IGH/CCND1 gene rearrangements was
performed on interphase nuclei using break apart
probes and a dual color dual fusion probe respectively
(Abbott Laboratories, Abbott Park, Illinois, USA).
Results
We identified 25 cases of pediatric B cell lym-
phoma (age range 3-19 years) with a high prolif-
erative index (Ki-67 ≥90%). According to 2008
WHO classification, the cases were classified as
19 Burkitt lymphomas, 4 DLBCL and two
monomorphic post-transplant lymphoprolifera-
tive disorders (m-PTLD) [1]. Aberrant CD5 ex-
pression was present in only one case.
Figure 1. Gross and histologic findings. Gross and histologic examination showed an ileal mass (A) which consists of a
diffuse infiltrate of lymphocytes extending through full-thickness bowel wall (B). The neoplastic cells are intermediate to
large in size with vesicular to coarse chromatin, variably visible nucleoli and scant to moderate amounts of cytoplasm ad-
mixed with frequent mitotic figures (including atypical mitosis) and apoptotic bodies. (C,D). B: H&E 20x, C: H&E 500x,
D: H&E 1000x.
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Clinical history.The patient was a 12 year-old boy
with no family history of malignancy and a past
medical history significant only for pervasive devel-
opmental disorder, not otherwise specified. He pre-
sented with approximately 6 weeks of diffuse vague
abdominal discomfort, which progressed to inter-
mittent episodes of severe pain associated with
bright red blood per rectum. Both upper and lower
gastrointestinal endoscopies were performed at an
outside institution and an ileocecal intussusception
with an intraluminal cecal mass was noted. Biopsy
of the mass revealed a hyperplastic polyp. The size
of the lesion prohibited endoscopic removal and an
ileocecal resection was scheduled. A laparoscopic
ileocecectomy with primary anastomoses was per-
formed at our institution; no lymphadenopathy or
hepatosplenomegaly was noted during intraopera-
tive examination. Post-operative laboratory values
demonstrated mild anemia (hemoglobin 10.6 g/
dL), a slightly elevated white blood cell count
(WBC 10.3 x 10(9)/L), and a serum lactate dehy-
drogenase (LDH) of 188 U/L (normal range 115-
221 U/L).
Gross examination. Gross examination of the
specimen showed a tan-red, firm, fungating mass in
the ileum measuring 4.5 cm in horizontal dimen-
sion, 3.0 cm in longitudinal dimension, and 1.4
cm in vertical dimension, located 0.5 cm from the
ileocecal valve and coming to within 0.1 cm of the
serosal surface (Figure 1A). The ileum appeared
partially intussuscepted into the cecum. No evi-
dence of perforation was seen. The appendix and
mesenteric fat were unremarkable.
Morphologic findings. Ileocecal Mass. Microscopic
examination showed a dense, full-thickness, diffuse
infiltrate of lymphocytes extending from the muco-
sal surface into the submucosa (Figure 1B). The
lymphocytes were intermediate to large in size with
oval to irregular nuclei, irregular nuclear contours,
vesicular to coarse chromatin, variably visible nu-
cleoli, and scant to moderate amounts of cytoplasm
(Figure 1C-D). Apoptotic debris and mitotic fig-
ures were abundant and areas of necrosis were not-
ed. Adjacent uninvolved small bowel and appendix
showed follicular hyperplasia, unremarkable small
bowel mucosa, and luminal mucinous exudates. Six
small lymph nodes were noted, all negative for in-
volvement by lymphoma (data not shown).
Bone marrow. Review of bilateral core needle bi-
opsy specimens and aspirate smears revealed a cel-
lular marrow with trilineage maturing
hematopoiesis.
Immunophenotypic findings. Ileocecal Mass. No
fresh tissue was available at the time of diagnosis,
precluding flow cytometric evaluation. An exten-
sive immunohistochemical marker panel was per-
formed, demonstrating that the neoplastic cells
were positive for CD5, CD10 (variable), CD20
(Figure 2A-C), CD43, CD44 (weak), CD79a,
bcl6, HGAL, and FOXP1 with weak expression of
bcl2 (data not shown). The cells were negative for
CD30, CD34, CD56, CD138, MUM1, TdT,
LMO2, Cyclin D1 (Figure 2D), and SOX11.
Antibodies for CD21 and CD23 did not show any
follicular dendritic cell meshwork and in situ hy-
bridization for EBER was negative (data not
shown). C-Myc was weakly positive in about 10
to 20% of neoplastic cells and Ki-67 demonstrated
a proliferation index of approximately 90%
(Figure 2E,F). CD3, CD5, and CD43 highlight-
ed admixed small background T-lymphocytes.
The combined morphologic and immunopheno-
typic findings were diagnostic of a mature B-cell
lymphoma, germinal center cell phenotype, with
high proliferation index and aberrant CD5
expression.
Bone marrow. Flow cytometric analysis of the bone
marrow aspirate sample and immunophenotypic
analysis of the core needle biopsy showed no evi-
dence of marrow involvement by lymphoma (data
not shown).
Cytogenetic analysis. Ileocecal mass. No fresh tu-
mor tissue was available at time of diagnosis which
precluded conventional cytogenetic karyotyping.
FISH analysis performed on paraffin-embedded
tissue sections was negative for IGH/CCND1 rear-
rangement and negative for cMYC, BCL6, BCL2,
and MLL rearrangement/amplification respective-
ly. The MLL (11q23) break apart probe showed
loss of one copy ofMLL in 31.7% (Figure 3).
Bone marrow. Karyotype analysis on the bone mar-
row aspirate revealed a normal male karyotype
(46,XY) without evidence of clonal chromosomal
abnormalities.
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Staging and Therapy. CSF analysis was negative
for lymphoma involvement. A whole body positron
emission tomography/computed tomography
(PET/CT) scan performed post-operatively identi-
fied mild FDG activity in the postoperative bed
and rare FDG-avid clusters in lymph nodes adja-
cent to the operative bed, suggestive of reactive in-
flammatory changes.
The patient was initially classified as having Stage II
disease, planned for two cycles of COPAD (cyclo-
phosphamide, vincristine, prednisolone, and doxo-
rubicin), and then later on upstaged, thus receiving
four cycles with the addition of methotrexate and
intrathecal therapy. The therapy was well tolerated
and end of therapy evaluation with PET/CT dem-
onstrated resolution of the previously described
Figure 2. Immunophenotypic findings. Immunohistochemical studies show the neoplastic cells are positive for CD20
(A), CD5 (B) and CD10 (C), while negative for Cyclin D1 (D). An antibody for c-Myc is positive in about 10-20% of
the neoplastic cells (E) and Ki-67 highlights a proliferation index of approximately 90% (F). A-F: 400x.
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FDG avidity in the surgical bed and adjacent lymph
nodes. No FDG avid disease was noted elsewhere.
A 6 month post end of therapy follow up PET/CT
showed no evidence of disease/relapse.
Discussion
Here we describe a case of a mature B-cell lympho-
ma with high proliferation index and aberrant CD5
expression that presented as an isolated extranodal
mass in a 12-year old boy causing an ileocecal intus-
susception. Initial differential diagnostic consider-
ations encompassed several B-cell lymphoprolifera-
tive neoplasms such as Burkitt lymphoma,
B-lymphoblastic leukemia/lymphoma, and less
likely, mantle cell lymphoma or a rare variant of
follicular lymphoma with aberrant CD5 expression
[9].
Immunophenotypic findings, particularly the lack
of immaturity markers, did not warrant a diagnosis
of B-lymphoblastic lymphoma. The patient’s age in
conjunction with the lack of Cyclin D1 and SOX11
expression by immunohistochemical marker analy-
sis as well as the lack of CCND1 abnormalities by
FISH analysis effectively ruled out a diagnosis of
mantle cell lymphoma. While a blastoid prolifera-
tion/variant of follicular lymphoma could be enter-
tained diagnostically, especially since a subset of
these cases can demonstrate CD5 expression and
may lack IGH/BCL2 gene rearrangement, the ma-
jority of these cases show a follicular growth pat-
tern, present with multifocal involvement/lymph-
adenopathy, elevated serum lactate dehydrogenase
(LDH) levels, elevated serum β2-microglobulin
levels, and are associated with higher International
Prognostic Index (IPI) scores [9]. Li et al. recently
analyzed 88 cases of CD5+ follicular lymphoma
and the youngest patient in their cohort was 31
years old [9]. As none of these characteristics were
present in our patient, a diagnosis of this rather un-
common B-cell lymphoma appeared less likely.
Figure 3. Fluorescent in situ hybridization (FISH) analysis results. Break apart probes for C-MYC, BCL2, and
MLL showed no evidence of rearrangement. The IGH/CCND1 dual color dual fusion probe showed no evidence of trans-
location. Loss of one copy of the MLL gene was noted in 31.7% of cells.
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In general age and localization of the tumor were
more consistent with a diagnosis of Burkitt lym-
phoma; however the proliferation index did not ap-
proach 100% as would be expected in Burkitt lym-
phoma. In addition, the observed cytological
pleomorphism along with aberrant CD5 expression
was rather unusual for a diagnosis of Burkitt lym-
phoma. While CD5 positive de novo Burkitt lym-
phoma cases have been described in the literature
[10], these cases all presented in elderly patients, in
a leukemic phase, with variable lymph node and
splenic involvement, typical Burkitt morphology,
high proliferative index, and most importantly,
cMYC rearrangement. None of these clinicopatho-
logical parameters were present in our case and
FISH analysis was negative for cMYC rearrange-
ment or amplification.
For these reasons along with the overall morpho-
logic and phenotypic features as well as the recogni-
tion of a specific subtype of DLBCL in adult pa-
tients, a diagnosis of CD5+ DLBCL was rendered.
To our knowledge, this is the first well-documented
case of a de novo CD5+ DLBCL occurring in a pe-
diatric patient.
De novo CD5-positive DLBCL has been well-char-
acterized in adults and represents approximately
5-10% of DLBCL in the adult setting. This entity
is distinctly different than other CD5+ lymphomas,
such as mantle cell lymphoma and Richter’s trans-
formation of chronic lymphocytic leukemia/small
lymphocytic lymphoma, in regards to combined
pathologic and clinical features. Though Richter’s
transformation presents with elevated LDH, B
symptoms, and advanced stage disease, extranodal
Richter's transformation is rare. In contrast, while
patients with de novo CD5+ DLBCL also tend to
present with elevated LDH levels, B symptoms, ad-
vanced clinical stage, and poor performance status,
these patients usually present with extranodal in-
volvement as well as frequent central nervous sys-
tem (CNS) involvement and do not have a preced-
ing history of a B-cell lymphoproliferative disorder
[5,11,12]. The clinico-pathological features of this
entity have been confirmed in several studies and
review articles in detail [5,11,13-16]. Notably, al-
though the median age in all studies ranged from
65 to 68 years, the youngest patient mentioned in
one series was 15 years of age (Table 1) [11].
However, further details on this patient were not
provided, and it is unknown if the patient had any
significant prior clinical history.
Four morphological variants of CD5+ DLBCL
have been described, including the common vari-
ant (centroblastic/monomorphic variant), the im-
munoblastic variant, the giant cell rich variant, and
the polymorphic variant [13].
Immunophenotypically, adult CD5+ DLBCL fall
more often within the ABC- DLBCL subgroup
with a typical immunophenotypic profile, charac-
terized as MUM1+, Foxp1+, GCET1-, CD10-,
and bcl6- [18]. They also commonly express bcl2
[5]. It is notable that our case rather belonged to
the germinal center B-cell (GCB) subtype, with
only weak bcl2 expression shown in a subset of cells
(data not shown). This finding is in concordance
with the fact that the majority of pediatric DLBCL
belong to the GCB subtype, with a characteristic
immunophenotype of GCET1+, CD10+, bcl6+,
MUM1-, and FoxP1- [19,20]. This GCB
Table 1. Summary of published cases of de novo CD5+ DLBCL and patient demographics.
Author Year Number of Median age Age range Percent > than
patients (years) (years) 60 years
Yamaguchi et al. [15] 2002 109 66 22-91 75%
Yoshioka et al. [7] 2005 23 67 40-86 NR*
Ennishi et al. [14] 2008 11 68 33-76 84%
Yamaguchi et al. [13] 2008 120 66 22-91 70%
Hyo et al. [16] 2010 19 66 30-91 NR*
Niitsu et al. [17] 2010 102 65 21-85 NR*
Miyazaki et al. [11] 2011 337 67 15-93 NR*
*Not reported
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predominance is also concordant with the fact that
pediatric DLBCL patients have, in general, an over-
all better prognosis than adults [21]. Other notable
characteristics of pediatric DLBCL include moder-
ate to high proliferation rates and increased c-Myc
protein expression.
Regarding cytogenetic and molecular features, sev-
eral differences exist between pediatric and adult
DLBCL cases. For example, BCL2 translocations
are rarely seen in children. On the contrary, translo-
cations involving the cMYC oncogene are more fre-
quent in pediatric DLBCL compared to adults
[22]. In adult CD5+ DLBCL, cytogenetic aberra-
tions have been shown to be similar to those occur-
ring in the ABC- DLBCL setting, including loss of
9p21 (p16INK4a locus), gains of 13q21.1-q34, loss
of 1p34.3-p36.21, and chromosome 8 aberrations
[5,7].
In our case FISH analysis for BCL2, BCL6 and
cMYC did not identify any abnormalities. FISH
analysis using the MLL (11q23) break-apart probe
showed no evidence of rearrangement; however,
loss of one copy ofMLL was seen in 31.7% of cells.
A recent study described a subset of MYC-negative
high-grade B-cell lymphomas resembling Burkitt
lymphoma that had recurrent aberrations in chro-
mosome 11q by gene expression analysis, suggest-
ing an alternate driving mechanism in some of
these neoplasms [23]. However, CD5 expression
was not described in any of these cases, and all pa-
tients presented more frequently with nodal in-
volvement and high LDH levels. In contrast, our
patient did not demonstrate any lymphadenopathy,
definitive nodal involvement, or LDH elevation.
Yoshioka et al. described different chromosomal ab-
errations involving chromosome 11 in de novoCD5
positive DLBCL [7]. They suggested that the entity
of CD5+ DLBCL can be further subdivided into at
least two groups that differed in overall survival.
They identified a group of patients with 11q13 ab-
normalities that showed better survival rates and a
group of patients with 8p21 abnormalities that was
associated with a worse prognosis. In addition, the
former group more often presented with localized
disease and had less LDH elevation [7].
The findings of the Yoshioka et al. study share some
similarities to our patient; however, none of the pa-
tients in this study were younger than age 40.
Therefore, it is not clear if this entity is biologically
and prognostically similar to our case.
Based on the lack of data on the prognostic signifi-
cance of CD5 expression in children, the unusual
presentation, the very remote possibility that a PET
avid lymph node next to the operative bed might be
involved by disease, and the fact that recurrent
DLBCL has a very low cure rate, our patient was
upstaged and thus received a more aggressive treat-
ment protocol. He tolerated the therapy very well
and both, an end of therapy and a 6 months post
therapy follow PET/CT scan confirmed complete
remission.
Conclusion. In summary, we present the first well-
described case of a de novo CD5+ DLBCL occur-
ring in a pediatric patient. We report this case to
emphasize the unusual presentation and we suggest
adding this entity to the extensive list of differential
diagnostic considerations in pediatric lymphoid
neoplasms. No comments regarding prognosis or
therapy can be made on the basis of a single patient;
however, it seems possible that the standard therapy
used for children carrying a diagnosis of DLBCL
may be appropriate.
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